Shanghai Junshi Biosciences’ JS207 Bispecific Antibody Receives NMPA Clinical Trial Approval
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1...
Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...
Germany-based pharmaceutical company Bayer (ETR: BAYN) has announced funding for three investigator-sponsored collaborative studies aimed...
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...
China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...
Merck, Sharp & Dohme (MSD; NYSE: MRK) has commenced Phase III development for its experimental...
China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...
China-based Youcare Pharmaceutical Group (SHA: 688658) has received ethical approval from the China-Japan Friendship Hospital...
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced that it has received clinical approval from...
China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd has recently obtained clinical trial...
China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received...
Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug...
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the...
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced the commencement of a Phase...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...
Hong Kong-based biotech company SinoMab BioScience Ltd (HKG: 3681) has announced that it has received...
CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of...